A high-quality biotech franchise with 25% revenue growth, strong margins, and a risk/reward ratio of approximately 5-to-1 is navigating a phase of technical deterioration — including a death cross and two consecutive earnings misses — that represents a near-term headwind rather than a structural change, provided quality fundamentals remain intact.
Thesis pillars
- High Quality Durable Margins→Stable
- Strong Revenue Growth Trajectory→Stable
- Favorable Risk Reward Asymmetry↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026· older than 90 days
Genmab A/S (GMAB) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $55.12, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Expensive valuation.
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma... Read more
Hold if already holding. Not a fresh buy at $55.12, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Expensive valuation. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.4/10, moderate confidence.
Passes 5/7 gates (positive momentum, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: speculative.
Recent developments
updated Oct 29, 2026Recent Developments — Genmab A/S
Latest news
- NEWS Genmab: Why I'd Wait Before Buying After A Stunning Series Of Study Results - Seeking Alpha — Seeking Alpha Oct 29, 2026 neutral
- NEWS GMAB Maintains Buy Rating -- Price Target Raised to $70.00 by HC Wainwright - GuruFocus — GuruFocus Oct 29, 2026 positive
- NEWS Genmab A/S Stock 12‑Month Price Target Raised to $50.14, Implies 12% Upside - TradingView — TradingView Oct 28, 2026 positive
- NEWS Genmab Shares Jump 30% as Head and Neck Cancer Combo Cuts Death Risk by Half - finance.biggo.com — finance.biggo.com Oct 28, 2026 positive
- NEWS Genmab stock surges 16% on positive cancer trial results - Investing.com — Investing.com Oct 28, 2026 positive
Latest item Oct 29, 2026 · Generated 2026-11-05T11:54:12Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $55.12, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Expensive valuation. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Analyst target $56.52 (+2.5%), stop $51.26 (−7.5%), A.R:R 0.2:1. Score 5.4/10, moderate confidence.
Analyst target: $56.52 (+2.5% upside). Analyst target $56.52 (+2.5%), stop $51.26 (−7.5%), A.R:R 0.2:1. Stop-loss: $51.26.
Analyst target reached - limited upside remaining; Expensive valuation; Overbought (RSI 84).
Genmab A/S trades at a P/E of 43.4 (forward 34.9). TrendMatrix value score: 2.8/10. Verdict: Hold.
25 analysts rate GMAB, with a consensus score of 3.8/5. 10 analysts publish price targets averaging $65.
What does Genmab A/S do?Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of...
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.